E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Subjects with life-threatening COVID-19 symptoms |
|
E.1.1.1 | Medical condition in easily understood language |
Subjects with life-threatening COVID-19 symptoms |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10051905 |
E.1.2 | Term | Coronavirus infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The overall objective of the study is to evaluate the efficacy of adding acalabrutinib to BSC for the treatment of COVID-19 |
|
E.2.2 | Secondary objectives of the trial |
To assess pharmacokinetics of acalabrutinib and its active metabolite in subjects with COVID-19 when administered with BSC
To evaluate the safety of acalabrutinib in
subjects with COVID-19 when
administered with BSC |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent
2. Men and women ≥18 years of age at the time of signing the informed consent form
3. Confirmed infection with SARS-CoV-2 confirmed per World Health Organization (WHO) criteria (including positive nucleic acid test of any specimen [eg, respiratory, blood, urine, stool, or other bodily fluid]) within 7 days of randomization
4. COVID-19 pneumonia (documented radiographically) requiring hospitalization and oxygen Saturation (Sp02) <94% on room air or requires supplemental oxygen
5. Able to swallow pills
6. Willing to follow contraception guidelines
|
|
E.4 | Principal exclusion criteria |
1. Respiratory failure at the time of screening due to COVID-19 pneumonia that impedes the ability to swallow pills, or in the opinion of the treating physician, the subject is likely to require mechanical Ventilation within the immediate 24 hours and therefore unable to swallow pills.
2. Known medical resuscitation within 14 days of randomization
3. Pregnant or breast feeding
4. Suspected uncontrolled active bacterial, fungal, viral, or other infection (besides infection with SARS-CoV-2)
5. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or Bilirubin ≥ 3× upper limit of normal (ULN) and/or severe hepatic impairment detected during the screening period (per local laboratory).
Exception: AST and/or ALT can be up to 5 × ULN if considered due to Underlying COVID-19 disease, but cannot be associated with concurrent elevated bilirubin (up to 2 × ULN).
6. Uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the last 6 weeks, or congestive heart failure (NYHA Grade 3 or 4). Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll
7. Treatment with a strong cytochrome P450 (CYP)3A inhibitor (within 7 days before first dose of study drug) or inducer (within 14 days before first dose of study drug)
8. Subjects are excluded who have already received Prior immunomodulatory/immunosuppressive treatment intended as specific treatment for COVID-19 (after randomization these agents may be
permitted ). Note: Steroids are permitted prior to randomization and on study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Endpoint is Proportion of subjects alive and free of
respiratory failure at Day 14.
For the purpose of this study, respiratory failure, is defined based on resource utilization of any of the following modalities:
(a) Endotracheal intubation and mechanical ventilation
(b) Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates >20L/min with fraction of delivered oxygen ≥0.5)
(c) Noninvasive positive pressure ventilation or continuous positive airway pressure
(d) Extracorporeal membrane oxygenation |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Proportion of subjects alive and free of respiratory failure (as defined above) at Day 28
Percent change from baseline in CRP (time frame: baseline, Days 3, 5, 7, 10, 14, 28)
Change from baseline in ferritin (time frame: baseline, Days 3, 5, 7, 10, 14, 28)
Change from baseline in absolute lymphocyte counts (time frame: baseline, Days 3, 5, 7, 10, 14, 28)
All-cause mortality at Day 90
Proportion of subjects alive and discharged from the ICU at Days 14 and 28
Time from randomization to first occurrence of respiratory failure or death on study (up to 28 days after randomization) due to any cause
Number of days alive and free of respiratory failure from randomization to 28 days after randomization
Number of days with respiratory failure from randomization to 28 days after randomization
Number of days hospitalized from randomization to 28 days after randomization
Number of days in ICU (length of stay) from randomization to 90 days after randomization
Number of days alive outside of hospital from randomization to 28 days after randomization
Number of days alive outside of hospital from randomization to 90 days after randomization
Relative change from baseline in oxygenation index (SpO2/FiO2) to Days 3, 5, 7 and 10
Type, frequency, severity, and relationship to study treatment of any TEAEs or abnormalities of laboratory tests, SAEs, or AEs leading to discontinuation of study treatment
Time to clinical improvement of at least 2 points (from randomization) on a 9-point category ordinal scale through Day 28 Time to SpO2 > 94% on room air
Summarized plasma concentrations of acalabrutinib and ACP-5862 at specified time points. PK parameters (eg, AUC and Cmax) estimated, as appropriate. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
approximately 28 days and for survival status approximately 90 days |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Brazil |
Chile |
France |
Germany |
Italy |
Japan |
Mexico |
Peru |
Russian Federation |
South Africa |
Spain |
Sweden |
Turkey |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 6 |